{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:16:36Z","timestamp":1789161396590,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.clim.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:39:22Z","timestamp":1548974362000},"page":"66-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-1459","authenticated-orcid":false,"given":"A.S.","family":"De Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.B.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2019.01.009_bb0005","series-title":"Scriver's OMMBID the Online Metabolic & Molecular Bases of Inherited Disease","article-title":"Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2009"},{"issue":"5","key":"10.1016\/j.clim.2019.01.009_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.clim.2019.01.009_bb0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.clim.2019.01.009_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.clim.2019.01.009_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clim.2019.01.009_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.clim.2019.01.009_bb0035","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.clim.2019.01.009_bb0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.clim.2019.01.009_bb0045","doi-asserted-by":"crossref","unstructured":"Desai, A.K., Z.B. Kazi, P.S. Kishnani, Cross-reactive immunologic material positive infantile Pompe disease: characterization of immune responses in patient treated with enzyme replacement therapy. Mol. Genet. Metab. 117(2): S41.","DOI":"10.1016\/j.ymgme.2015.12.240"},{"key":"10.1016\/j.clim.2019.01.009_bb0050","series-title":"[Package Insert]. Genzyme Corporation","author":"Lumizyme","year":"2016"},{"issue":"1","key":"10.1016\/j.clim.2019.01.009_bb0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.clim.2019.01.009_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.clim.2019.01.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy\u2013treated CRIM-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.clim.2019.01.009_bb0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","article-title":"Immunogenicity of protein therapeutics","volume":"28","author":"De Groot","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2019.01.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/961752","article-title":"A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM)","volume":"2010","author":"Cohen","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"19","key":"10.1016\/j.clim.2019.01.009_bb0080","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/S0264-410X(98)00173-X","article-title":"Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix","volume":"16","author":"Schafer","year":"1998","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.clim.2019.01.009_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul. Disord."},{"issue":"17","key":"10.1016\/j.clim.2019.01.009_bb0090","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1016\/j.vaccine.2011.02.019","article-title":"Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus","volume":"29","author":"Schanen","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.clim.2019.01.009_bb0095","first-page":"203","article-title":"Measures of diagnostic accuracy: basic definitions","volume":"19","author":"Simundic","year":"2009","journal-title":"EJIFCC"},{"issue":"2","key":"10.1016\/j.clim.2019.01.009_bb0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.clim.2019.01.009_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.clim.2019.01.009_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ymgmr.2015.05.004","article-title":"Immune Tolerance strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"10.1016\/j.clim.2019.01.009_bb0115","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/hv.24615","article-title":"The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix","volume":"9","author":"Moise","year":"2013","journal-title":"Hum Vaccin Immunother"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618305825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618305825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:21:18Z","timestamp":1553646078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618305825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":23,"alternative-id":["S1521661618305825"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.01.009","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}